Clinicopathological features and prognostic analysis of gastrointestinal stromal tumor with liver metastasis

赵锐,万谦益,王勇,崔亚平,伍羽韬,伍晓汀

DOI: https://doi.org/10.3760/cma.j.cn101548-20200221-00004

2020-01-01

Abstract:Objective:To investigate and compare the clinicopathological features of patients with gastrointestinal stromal tumor (GIST) with liver metastasis and patients with high risk GIST without liver metastasis, and to identify references for diagnosis and treatment of GIST with liver metastasis.Methods:118 patients diagnosed with GIST at West China Hospital of Sichuan University Department of Gastrointestinal Surgery from 2014 to 2019 were retrospectively included in this study. Among them, 56 patients had GIST with liver metastasis, and 62 patients had high risk GIST without liver metastasis. The major clinicopathological features of patients were collected and prognostic analysis was performed.Results:The median follow-up time were 31 months (8~65 months). Compared with patients without liver metastasis, those with liver metastasis were significantly younger ( P=0.01). There were no statistical differences in sex, site and size of primary tumor, expression of CD117, CD34, DOG1, Ki67 and gene mutation between the two groups. The mitotic activity of patients with liver metastasis were significantly higher than those without liver metastasis ( P=0.02). Patients without liver metastasis had significantly longer recurrence-free survival ( P=0.03), while the two groups had similar overall survival ( P=0.83). Conclusions:The malignancy of GIST with liver metastasis might be higher than GIST of high risk without metastasis. R0 resection and postoperative adjuvant therapy were crucial for the treatment of GIST with liver metastasis. The duration and protocol of tyrosine kinase inhibitor treatment for GIST with liver metastasis need further studies.